{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:13:31Z","timestamp":1789438411041,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010099","name":"Institute of Organic Chemistry and Biochemistry AS CR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejmech.2021.113416","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T20:02:17Z","timestamp":1617480137000},"page":"113416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Nucleotide analogues containing a pyrrolidine, piperidine or piperazine ring: Synthesis and evaluation of inhibition of plasmodial and human 6-oxopurine phosphoribosyltransferases and in\u00a0vitro antimalarial activity"],"prefix":"10.1016","volume":"219","author":[{"given":"Jan","family":"Frydrych","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne T.","family":"Keough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Chavchich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7659-1877","authenticated-orcid":false,"given":"Jye","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dra\u010d\u00ednsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Edstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke W.","family":"Guddat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hockov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Janeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113416_bib1","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00044-014-1295-3","article-title":"A\u00a0comprehensive review on bioactive fused heterocycles as purine-utilizing enzymes inhibitors","volume":"24","author":"Chauhan","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113416_bib2","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2174\/092986710791556023","article-title":"Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?","volume":"17","author":"Berg","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jmb.2005.05.061","article-title":"The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle","volume":"351","author":"Keough","year":"2005","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113416_bib4","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1021\/bi990664p","article-title":"The 2.0 \u00c5 structure of malarial purine phosphoribosyltransferase in complex with transition-state analogue inhibitor","volume":"38","author":"Shi","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113416_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.pt.2020.03.009","article-title":"Plasmodium vivax in the era of the shrinking P.\u00a0falciparum map","volume":"36","author":"Price","year":"2020","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2021.113416_bib6","doi-asserted-by":"crossref","first-page":"8365","DOI":"10.1021\/acs.jmedchem.9b00182","article-title":"Plasmodium purine metabolism and its inhibition by nucleoside and nucleotide analogues","volume":"62","author":"Cheviet","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib7","doi-asserted-by":"crossref","first-page":"32889","DOI":"10.1074\/jbc.M804497200","article-title":"Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum","volume":"283","author":"Cassera","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1042\/BJ20140240","article-title":"From crystal to compound: structure-based antimalarial drug discovery","volume":"461","author":"Drinkwater","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2021.113416_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.05.043","article-title":"New dimensions in the field of antimalarial research against malaria resurgence","volume":"181","author":"Narula","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/156802611796575911","article-title":"6-Oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs","volume":"11","author":"de Jersey","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cmdc.201700293","article-title":"Acyclic nucleoside phosphonates containing 9-deazahypoxanthine and a 5-membered heterocycle as selective inhibitors of plasmodial 6-oxopurine phosphoribosyltransferases","volume":"12","author":"Kaiser","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113416_bib12","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.bmc.2017.05.048","article-title":"Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs","volume":"25","author":"\u0160pa\u010dek","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1021\/jm501416t","article-title":"Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents","volume":"58","author":"Keough","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib14","doi-asserted-by":"crossref","first-page":"11194","DOI":"10.1021\/acs.chemrev.8b00369","article-title":"Enzymatic transition states and drug design","volume":"118","author":"Schramm","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113416_bib15","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1021\/jm061012j","article-title":"Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases","volume":"49","author":"Keough","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib16","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1021\/jm900267n","article-title":"Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics","volume":"52","author":"Keough","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/9367","article-title":"Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases","volume":"6","author":"Li","year":"1999","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113416_bib18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4155\/fmc.13.51","article-title":"Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria","volume":"5","author":"Ducati","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111667","article-title":"Sulfide, sulfoxide and sulfone bridged acyclic nucleoside phosphonates as inhibitors of the Plasmodium falciparum and human 6-oxopurine phosphoribosyltransferases: synthesis and evaluation","volume":"183","author":"Klejch","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib20","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1016\/j.bmc.2013.02.016","article-title":"Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase","volume":"21","author":"Clinch","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib21","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1021\/acs.jmedchem.7b00926","article-title":"Synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of plasmodium falciparum and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferase","volume":"60","author":"\u0160pa\u010dek","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib22","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1016\/j.bmc.2015.07.038","article-title":"Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases","volume":"23","author":"Hockov\u00e1","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/acschembio.7b00916","article-title":"Design of plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase inhibitors as potential antimalarial therapeutics","volume":"13","author":"Keough","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113416_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.chembiol.2012.04.012","article-title":"Acyclic immucillin phosphonates: second-generation inhibitors of plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase","volume":"19","author":"Hazleton","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113416_bib25","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/jm300662d","article-title":"Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, plasmodium falciparum and plasmodium vivax 6-oxopurine phosphoribosyltransferases","volume":"55","author":"Hockov\u00e1","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib26","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.1021\/acs.jmedchem.6b00523","article-title":"Nucleoside phosphate and phosphonate prodrug clinical candidates","volume":"59","author":"Thornton","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib27","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"18","author":"Pradere","year":"2014","journal-title":"Chem. Rev."},{"issue":"614","key":"10.1016\/j.ejmech.2021.113416_bib28","first-page":"737","volume":"4","author":"Hamanaka","year":"1986","journal-title":"U.S. Patent"},{"issue":"A1","key":"10.1016\/j.ejmech.2021.113416_bib29","author":"Rudolf","year":"2004","journal-title":"U.S. patent 2004192729"},{"key":"10.1016\/j.ejmech.2021.113416_bib30","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1016\/j.tet.2018.08.014","volume":"74","author":"Klejch","year":"2018","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2021.113416_bib31","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1016\/j.ejmech.2011.05.040","volume":"46","author":"Jansa","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1039\/B413173H","volume":"3","author":"Butts","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2021.113416_bib33","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/cmdc.201500322","article-title":"Synthesis and evaluation of novel acyclic nucleoside phosphonates as inhibitors of plasmodium falciparum and human 6-oxopurine","volume":"10","author":"Kaiser","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113416_bib34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1126\/science.781840","article-title":"Human malaria parasites in continuous culture","volume":"193","author":"Trager","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113416_bib35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2307\/3280287","article-title":"Synchronization of Plasmodium falciparum erythrocytic stages in culture","volume":"65","author":"Lambros","year":"1979","journal-title":"J.\u00a0Parasitol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:29:31Z","timestamp":1759328971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421002658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"alternative-id":["S0223523421002658"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113416","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleotide analogues containing a pyrrolidine, piperidine or piperazine ring: Synthesis and evaluation of inhibition of plasmodial and human 6-oxopurine phosphoribosyltransferases and in\u00a0vitro antimalarial activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113416"}}